Merck and the University of Cape Town to Develop a Drug Discovery Platform for Malaria

23-Nov-2015 - South Africa

Merck announced that a research agreement has been signed with the University of Cape Town (UCT) South Africa to co-develop a new R&D platform aimed at identifying new lead programs for potential treatments against malaria, with the potential to expand it to other tropical diseases.

Combining Merck’s R&D expertise and the drug discovery capabilities of the UCT Drug Discovery and Development Centre, H3D, the collaboration will conduct drug discovery research with the goal of developing anti-malarial drug candidates using Merck’s compound library.

“This strategic collaboration shows the commitment of Merck to provide access to medicines for underserved populations, while creating a potential long-term alliance for generating new drugs to treat infectious diseases,” said Beatrice Greco, Head of Malaria and Diagnostics - Global Health R&D, within the biopharmaceutical business of Merck.

Other news from the department science

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Agilent Thought Leader Award Presented to Renowned Drug Discovery Researcher Professor - Award to Chinese Scientist Supports the Use of Various Molecular Approaches to Cancer Research

Vitamins doing gymnastics: Scientists capture first full image of vitamin B12 in action - Work by University of Michigan and MIT team yields new understanding of crucial reaction in the body and in CO2-scrubbing bacteria

Positive Results in Proof-of-Concept Study with Sustained Release Treatment for Uveitis

Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - Abbott will retain its branded generics pharmaceuticals business in emerging markets

Stanford researchers explore link between human birth defect syndrome, cancer metastasis

Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan

Pharmacogenomics study finds rare gene variants critical for personalized drug treatment

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection

Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition

Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology

Synthetic chemistry approach yields new compounds with potential biomedical applications - The study marks a significant advancement in chemical synthesis techniques, leveraging modern organic chemistry and engineered enzymes

Synthetic chemistry approach yields new compounds with potential biomedical applications - The study marks a significant advancement in chemical synthesis techniques, leveraging modern organic chemistry and engineered enzymes